A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells

Trish T. Hoang(University of Wisconsin–Madison), Ronald T. Raines(Broad Institute)
Molecular Cancer Therapeutics
October 3, 2018
Cited by 7


Related Papers